Natco Pharma Limited
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Natco Pharma Limited
India’s Natco has struck a deal with Celgene to settle litigation over its proposed generic lenalidomide rival to Revlimid in Canada. News of the settlement came shortly after the Indian firm reported a decline in quarterly and annual revenues following supply chain disruptions caused by the coronavirus crisis.
While Novartis is continuing to provide hydroxychloroquine for ongoing investigator-initiated trials and support for study of a potential vaccine, it has decided to stop sponsoring hydroxychloroquine clinical trials. Meanwhile, Natco has announced donations of chloroquine phosphate for clinical trials, while Centrient and Beximco have provided PPE for healthcare workers.
The past decade witnessed a bout of pharma 'shock and awe' events in India, some of which still reverberate across the industry. The period also marked the death of doyens of the Indian pharmaceutical sector, including the founders of Dr Reddy’s and Lupin.
Vildagliptin formulation prices fall by over 70% following the expiry of a patent held by Novartis in India. The innovator, meanwhile, is cashing in on co-marketing agreements with Indian partners like USV and Cipla
- Generic Drugs